Repligen Corporation (RGEN)

NASDAQ • Healthcare

$181.7

+$4.46 (+2.5%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$179.32

Day Range$178 - $186.52

Avg. Volume (3M)1.1M

Market Cap$10.2B

P/E Ratio245.5

52 Week Range

$100.99$198.87

Next EarningsIn 30 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$204.1M100%

Gross Profitminus cost of goods$108.3M53%

Operating Incomeminus R&D and overhead$11.9M6%

Net Incomeminus taxes and the rest$5M2%

In plain terms: out of every $100 in revenue, Repligen Corporation keeps $2 as net profit.

Fundamentals & Financials

Revenue (TTM)

$785.1M

Net Income (TTM)

$41.5M

EPS (TTM)

$0.74

ROA (TTM)

1.41%

Current Ratio

9.05

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-7.5%Q3 2025$0.37

+9.5%Q4 2025$0.46

+11.4%Q1 2026$0.49

+26.3%Q2 2026$0.48

+20.8%Q3 2026$0.54

Nov 3

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +20.8%

Repligen beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 28, with adjusted EPS of $0.54 topping the $0.45 estimate (+21%) and revenue of $204.1 million topping the $201.6 million estimate (+1.3%). Revenue rose ~12% to about $204.1 million from roughly $182.4 million a year ago, while net income fell ~66% to around $5.0 million versus about $14.9 million in the prior-year quarter. Profitability included gross profit of roughly $108.4 million and a gross margin near 53%, alongside operating income of about $11.9 million for an operating margin around 6%. The company generated operating cash flow of approximately $32.8 million and repurchased about $1.1 million of stock. Next-period consensus calls for EPS of $0.46 on revenue of $206.8 million.

View full earnings history

About Repligen Corporation

Repligen Corporation develops and sells bioprocessing equipment, materials, and integrated systems for biologic drug manufacturing and related laboratory work. Listed on the NASDAQ as RGEN, the healthcare company operates in the medical instruments and supplies business and generated $738.3 million of revenue in FY2025.

Name

Repligen Corporation

CEO

Olivier Loeillot

Website

www.repligen.com

Industry

Healthcare

Year Founded

1981

Employees

2,000

Today's Snapshot

AI-generated

RGEN closed 2.5% above yesterday's close, while its sector was flat.

Trading Volume

Above 10d avg 1.3M

1.3M

vs S&P 500 Today

Outperforming Market

+1.74%

Updated: October 2, 2026 at 20:12 UTC

RGEN Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read

View All News

Technical Indicators

4 Buy3 Neutral1 Sell

Repligen shows a favorable technical setup at 181.70, supported by a robust ADX that indicates a strong underlying trend and positive volume accumulation on OBV. The price is above key medium- and long-term averages even though the very short-term moving average lies higher, and momentum measures are mildly positive while MACD is holding near positive territory. Volatility is moderate and the pivot is just above the market, suggesting nearby resistance. Technical takeaway: Buy bias backed by trend strength and supportive volume.

All signals